Clinical Trials Directory

Trials / Terminated

TerminatedNCT01963728

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Comparison of Insulin Isophane (NPH) With Insulin Glargine in New Onset Diabetes After Transplant (NODAT)

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
2 (actual)
Sponsor
Inova Health Care Services · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).

Detailed description

A large percentage of organ transplant recipients develop de novo diabetes mellitus after transplantation, also called "New Onset Diabetes After Transplant" or NODAT. The cause of the diabetes appears to be commonly used anti-rejection medications, particularly calcineurin inhibitors and glucocorticoids. Management of glucose levels in NODAT often requires insulin therapy. Standard practice is to start long-acting insulin. However, patients with NODAT often exhibit fasting morning glucose levels that are relatively low compared to pre-lunch and pre-dinner glucose levels. This seems to make NODAT patients more susceptible to fasting, or morning, hypoglycemia on long-acting insulin analogues than non-transplant patients with type II diabetes. This phenomenon of morning hypoglycemia in NODAT often limits the up-titration of basal insulin resulting in suboptimal treatment of hyperglycemia later in the day. Because of this pattern, transplant patients may respond better to morning insulin isophane (intermediate acting) than to long-acting insulin glargine preparations. Our trial is designed to compare morning NPH insulin (isophane insulin) with conventional therapy of basal glargine insulin on both continuous blood glucose levels and hemoglobin A1c (glycosylated hemoglobin).

Conditions

Interventions

TypeNameDescription
DRUGInsulin, Isophanedaily dosing based on fasting morning glucose levels
DRUGinsulin glarginedaily dose based on fasting morning glucose levels

Timeline

Start date
2013-11-27
Primary completion
2015-04-09
Completion
2015-04-09
First posted
2013-10-16
Last updated
2022-07-26
Results posted
2022-01-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01963728. Inclusion in this directory is not an endorsement.